Syndax Pharmaceuticals Inc（SNDX）財務資料SNDXSyndax Pharmaceuticals Inc

Evaluating the bottom line, Syndax Pharmaceuticals, Inc. maintains a gross margin of 95.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -54.95%, while the net margin is -67.82%. These profitability ratios, combined with a Return on Equity (ROE) of -255.93%, provide a clear picture of how effectively SNDX converts its operational activities into shareholder value.

In the context of the broader market, SNDX competes directly with industry leaders such as IAM and CTY. With a market capitalization of $1.21B, it holds a leading position in the sector. When comparing efficiency, SNDX's gross margin of 95.59% stands against IAM's N/A and CTY's N/A. Such benchmarking helps identify whether Syndax Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Syndax's gross margin remains strong at 95.76% in Q2 2026, indicating effective cost management despite ongoing net losses. The company has shown a narrowing net loss trend, reducing from $71.85 million in Q2 2025 to $49.36 million in Q2 2026, reflecting improved financial management.